Biotech Walloped On Clinton Drug Price Controls Threat
This article was originally published in Scrip
Executive Summary
It was déjà vu all over again on Wall Street on Sept. 21 when biotech stocks took a beating after a powerful Washington politician vowed to take action to control prescription drug prices – a whipping reminiscent of March 2014 after three Democratic lawmakers set off a frenzy by suggesting they may pursue a similar path when they called on Gilead Sciences to explain its $1,000-per-pill price for its hepatitis C virus (HCV) medicine Sovaldi (sofosbuvir).
You may also be interested in...
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Drug makers are embracing different strategies on the pricing issue as the industry marches closer to a confrontation with President-Elect Trump over the cost of medicines.
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.